Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma

26-May-2015 - Germany

Isarna Therapeutics announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, for the prevention of scarring post filtration surgery in glaucoma. With EMA Orphan Drug Designation, Isarna is eligible for development fee reductions and incentives including 10-year market exclusivity for ISTH0036.

“Orphan designation for ISTH0036 in the European Union (EU) is a substantial accomplishment and corporate milestone for Isarna,” said Dr. Philippe Calais, President and Chief Executive Officer of Isarna Therapeutics. “Currently, patients with advanced-stage glaucoma have limited long-term treatment options. The EMA’s recognition of the potential of ISTH0036 to help protect glaucoma patients’ vision in this stage of their disease with orphan drug status is a significant step forward for the ongoing development of this novel therapy.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances